Hong Lee Trading Inc. Issues Allergen Alert On Undeclared Milk Allergens In Vina Café Wake-Up Instant Coffee - FDA Safety Alerts & Drug Recalls

Hong Lee Trading Inc., NY, is recalling its VINA CAFÉ WAKE-UP INSTANT COFFEE MIX in 18 PACK CARDBOARD BOXES (.6 oz packs), with lot “EXP:17.MAR.2019 1T13.” because they contain undeclared milk allergens. Consumers who are allergic to milk allergens may run the risk of serious or life-threatening allergic reactions if they consume this product.

from Food and Drug Administration--Recalls/Safety Alerts http://ift.tt/2xNEIOg
via IFTTT

Greencore USA, LLC Recalls Chicken Salad and Ham Sandwiches and Seafood Stuffing Because of Possible Health Risk - FDA Safety Alerts & Drug Recalls

Greencore, USA, LLC is voluntarily recalling egg salad sandwiches, ham salad sandwiches, and seafood stuffing as listed below. The products are being recalled because Listeria monocytogenes was found in environmental sampling conducted by FDA.

from Food and Drug Administration--Recalls/Safety Alerts http://ift.tt/2xMRg8o
via IFTTT

Chun Yuen Trading Co. Issues Allergy Alert On Undeclared Milk - FDA Safety Alerts & Drug Recalls

Chun Yuen Trading Co. of South El Monte, California, is recalling its 12.7 oz of 4-in-1 Reishi Coffee due to a mislabeling of the outer packaging, which contains undeclared milk content. People who are allergic to milk run the risk of serious or life threatening allergic reaction if they consume these products.

from Food and Drug Administration--Recalls/Safety Alerts http://ift.tt/2yyU8TU
via IFTTT

Global Sensory Impairment Predicts Morbidity and Mortality in Older U.S. Adults - American Geriatric Society

Objectives

To evaluate global sensory impairment (GSI, an integrated measure of sensory dysfunction) as a predictor of physical function, cognition, overall health, and mortality.

Design

Prospective study.

Setting

The National Social Life, Health, and Aging Project.

Participants

A national probability sample of 3,005 home-dwelling older U.S. adults assessed at baseline (2005–06) and 5-year follow-up (2010–11).

Measurements

Gait speed, activity, disability, cognition, overall health, 5-year mortality.

Results

At baseline, older adults with worse GSI were slower (Timed Up and Go times: odds ratio (OR) = 1.32, 95% confidence interval (CI) = 1.17–1.50) and had more activity of daily living deficits (≥2: OR = 1.26, 95% CI = 1.10–1.46). Five years later, they were still slower (timed walk: OR = 1.22, 95% CI = 1.05–1.42), had more disabilities (≥2 instrumental activities of daily living; OR = 1.45, 95% CI = 1.23–1.70), were less active (daytime activity according to accelerometry: β = −2.7, 95% CI = −5.2 to −0.2), had worse cognitive function (Montreal Cognitive Assessment; β = −0.64, 95% CI = −0.84 to −0.44), more likely to have poorer overall health (OR = 1.16, 95% CI = 1.03–1.31) and lose weight (>10%: OR = 1.31, 95% CI = 1.04–1.64), and have died (OR = 1.45, 95% CI = 1.19–1.76). All analyses were adjusted for relevant confounders at baseline, including age, sex, race and ethnicity, education, smoking, problem drinking, body mass index, comorbidities, and cognitive function.

Conclusion

GSI predicts impaired physical function, cognitive dysfunction, significant weight loss, and mortality 5 years later in older U.S. adults. Multisensory evaluation may identify vulnerable individuals, offering the opportunity for early intervention to mitigate adverse outcomes.

from Journal of the American Geriatrics Society http://ift.tt/2wdGt48
via IFTTT

FDA improves access to reports of adverse drug reactions - FDA Press Releases

The U.S. Food and Drug Administration today launched a new user-friendly search tool that improves access to data on adverse events associated with drug and biologic products through the FDA’s Adverse Event Reporting System (FAERS). The tool is designed to make it easier for consumers, providers, and researchers to access this information.

from Food and Drug Administration--Press Releases http://ift.tt/2x0lUYu
via IFTTT

FDA approves new treatment for certain advanced or metastatic breast cancers - FDA Press Releases

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).

from Food and Drug Administration--Press Releases http://ift.tt/2hzEx3u
via IFTTT

FDA approves first continuous glucose monitoring system for adults not requiring blood sample calibration - FDA Press Releases

The U.S. Food and Drug Administration today approved the FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adult patients to make diabetes treatment decisions without calibration using a blood sample from the fingertip (often referred to as a “fingerstick”).

from Food and Drug Administration--Press Releases http://ift.tt/2fspm7S
via IFTTT